Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

OBJECTIVES: To investigate the efficacy and safety of peficitinib, an oral Janus kinase inhibitor, in patients with rheumatoid arthritis (RA). METHODS: In this double-blind phase III study, patients with RA and an inadequate response to prior disease-modifying anti-rheumatic drugs (DMARDs) were rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Takeuchi, Tsutomu, Tanaka, Sakae, Kawakami, Atsushi, Iwasaki, Manabu, Song, Yeong Wook, Chen, Yi-Hsing, Wei, James Cheng-Chung, Lee, Sang-Heon, Rokuda, Mitsuhiro, Izutsu, Hiroyuki, Ushijima, Satoshi, Kaneko, Yuichiro, Akazawa, Rio, Shiomi, Teruaki, Yamada, Emi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788921/
https://www.ncbi.nlm.nih.gov/pubmed/31350270
http://dx.doi.org/10.1136/annrheumdis-2019-215163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788921/
https://www.ncbi.nlm.nih.gov/pubmed/31350270
http://dx.doi.org/10.1136/annrheumdis-2019-215163

Ejemplares similares